Daiichi Sankyo Europe Develops Fixed-Triple Oral Combination for LDL-C Reduction

Daiichi Sankyo Europe has announced the development of a fixed-triple oral lipid-lowering tablet combining bempedoic acid, ezetimibe, and varying doses of a statin, designed to further lower low-density lipoprotein cholesterol (LDL-C) levels.

Since bempedoic acid and ezetimibe are already available as a single-dose therapy, adding flexible statin dosing within one pill could help physicians better individualize treatment for patients. “This oral triple combination underscores our commitment to improving cardiovascular care and tailoring treatment to patient needs,” said Dr. Stefan Seyfried, Vice President, Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe.

The program builds on insights from the MILOS and SANTORINI registries, which highlight persistent gaps in LDL-C control and health disparities, particularly among women.

Professor Kausik Ray (Imperial College London) stressed that while cholesterol management has advanced, inconsistencies in LDL-C treatment remain, reinforcing the need for solutions like combination medicines. Similarly, Professor Raj Thakkar (Primary Care Cardiovascular Society) emphasized the importance of systematic lipid management and the role of combination therapies in reducing cardiovascular risk efficiently and sustainably.